JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Setting

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Home
Signaling Pathways

Signaling Pathways

B2140 Calcifediol

Target: Vitamin D receptors (VDRs)

Summary: Major circulating form of vitamin D3

insoluble in H2O; ≥13.65 mg/mL
B1527 GW4064

Target: FXR

Summary: Non-steroidal FXR agonist,potent and selective

insoluble in H2O; insoluble in EtOH; ≥24.7 mg/mL
B1639 Ridaforolimus (Deforolimus, MK-8669)

Target: mTOR

Summary: MTOR inhibitor

≥49.5 mg/mL
B1528 XL335

Target: Farnesoid X receptors (FXRs)

Summary: FXR agonist

insoluble in H2O; insoluble in EtOH; ≥20.4 mg/mL
B1465 Plerixafor 8HCl (AMD3100 8HCl)

Target: CXCR

Summary: CXCR4 antagonist

≥155.4 mg/mL
B1036 MLN4924

5 Citation

Target: NAE|Ubiquitin-activating Enzyme E1|SUMOylation

Summary: NAE inhibitor

≥22.18 mg/mL
B2224 Etravirine (TMC125)

Target: Reverse Transcriptases

Summary: Reverse transcriptase inhibitor

insoluble in EtOH; insoluble in H2O; ≥19.35 mg/mL
B1620 Tolterodine tartrate

Target: AChR

Summary: Competitive muscarinic receptor antagonist

≥23.78 mg/mL
B1614 Solifenacin succinate

Target: M3 Receptors

Summary: Muscarinic receptor antagonist

≥24.05 mg/mL
B1600 Darifenacin HBr

Target: M3 Receptors

Summary: Selective M3 muscarinic receptor antagonist

insoluble in EtOH; insoluble in H2O; ≥20.2 mg/mL